Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer

Zheng Han, Shuixing Zhang, Kenji Fujiwara, Jia Zhang, Yuguo Li, Jing Liu, Peter C.M. Van Zijl, Zheng Rong Lu, Lei Zheng, Guanshu Liu

Research output: Contribution to journalArticle

Abstract

A dextran-peptide conjugate was developed for magnetic resonance (MR) molecular imaging of pancreatic ductal adenocarcinoma (PDAC) through its overexpressed microenvironment biomarker, extradomain-B fibronectin (EDB-FN). This new agent consists of diamagnetic and biocompatible dextran and a targeting peptide. Dextrans can be directly detected by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) without the need for radionuclide or metallic labeling. In addition, large molecular weight dextran, dextran 10 (MW ∼ 10 kDa), provides an approximately 50 times higher sensitivity per molecule than a single glucose unit. The potential of this highly biocompatible diamagnetic probe is demonstrated in a murine syngeneic allograft PDAC tumor model. The biocompatibility and sensitivity of this new agent clearly show potential for a path to clinical translation.

Original languageEnglish (US)
JournalBioconjugate Chemistry
DOIs
StatePublished - Jan 1 2019

Fingerprint

Dextran
Dextrans
Pancreatic Neoplasms
Fibronectins
Magnetic Resonance Imaging
Magnetic resonance
Peptides
Adenocarcinoma
Molecular imaging
Molecular Imaging
Critical Pathways
Biomarkers
Biocompatibility
Radioisotopes
Labeling
Allografts
Glucose
Tumors
Molecular Weight
Molecular weight

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

@article{264fb3dd090043eda96394b636418969,
title = "Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer",
abstract = "A dextran-peptide conjugate was developed for magnetic resonance (MR) molecular imaging of pancreatic ductal adenocarcinoma (PDAC) through its overexpressed microenvironment biomarker, extradomain-B fibronectin (EDB-FN). This new agent consists of diamagnetic and biocompatible dextran and a targeting peptide. Dextrans can be directly detected by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) without the need for radionuclide or metallic labeling. In addition, large molecular weight dextran, dextran 10 (MW ∼ 10 kDa), provides an approximately 50 times higher sensitivity per molecule than a single glucose unit. The potential of this highly biocompatible diamagnetic probe is demonstrated in a murine syngeneic allograft PDAC tumor model. The biocompatibility and sensitivity of this new agent clearly show potential for a path to clinical translation.",
author = "Zheng Han and Shuixing Zhang and Kenji Fujiwara and Jia Zhang and Yuguo Li and Jing Liu and {Van Zijl}, {Peter C.M.} and Lu, {Zheng Rong} and Lei Zheng and Guanshu Liu",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acs.bioconjchem.9b00161",
language = "English (US)",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer

AU - Han, Zheng

AU - Zhang, Shuixing

AU - Fujiwara, Kenji

AU - Zhang, Jia

AU - Li, Yuguo

AU - Liu, Jing

AU - Van Zijl, Peter C.M.

AU - Lu, Zheng Rong

AU - Zheng, Lei

AU - Liu, Guanshu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A dextran-peptide conjugate was developed for magnetic resonance (MR) molecular imaging of pancreatic ductal adenocarcinoma (PDAC) through its overexpressed microenvironment biomarker, extradomain-B fibronectin (EDB-FN). This new agent consists of diamagnetic and biocompatible dextran and a targeting peptide. Dextrans can be directly detected by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) without the need for radionuclide or metallic labeling. In addition, large molecular weight dextran, dextran 10 (MW ∼ 10 kDa), provides an approximately 50 times higher sensitivity per molecule than a single glucose unit. The potential of this highly biocompatible diamagnetic probe is demonstrated in a murine syngeneic allograft PDAC tumor model. The biocompatibility and sensitivity of this new agent clearly show potential for a path to clinical translation.

AB - A dextran-peptide conjugate was developed for magnetic resonance (MR) molecular imaging of pancreatic ductal adenocarcinoma (PDAC) through its overexpressed microenvironment biomarker, extradomain-B fibronectin (EDB-FN). This new agent consists of diamagnetic and biocompatible dextran and a targeting peptide. Dextrans can be directly detected by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) without the need for radionuclide or metallic labeling. In addition, large molecular weight dextran, dextran 10 (MW ∼ 10 kDa), provides an approximately 50 times higher sensitivity per molecule than a single glucose unit. The potential of this highly biocompatible diamagnetic probe is demonstrated in a murine syngeneic allograft PDAC tumor model. The biocompatibility and sensitivity of this new agent clearly show potential for a path to clinical translation.

UR - http://www.scopus.com/inward/record.url?scp=85064992402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064992402&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.9b00161

DO - 10.1021/acs.bioconjchem.9b00161

M3 - Article

C2 - 30938983

AN - SCOPUS:85064992402

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

ER -